They developed a SERS LFT for the detection of neuron-specific enolase (NSE), a biomarker of brain injury (and also a biomarker for tumors such as neuroblastoma and small cell lung cancer) in blood plasma. This evidence concerns the gene ENO2 and neuroblastoma.